{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:56:29Z","timestamp":1767664589558},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clinthera.2015.08.023","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T16:44:13Z","timestamp":1443372253000},"page":"2347-2351","source":"Crossref","is-referenced-by-count":19,"title":["Prevention of Recurrent Pterygium with Topical Bevacizumab 0.05% Eye Drops: A Randomized Controlled Trial"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01311960","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ngamjit","family":"Kasetsuwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usanee","family":"Reinprayoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vannarut","family":"Satitpitakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.08.023_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ICU.0b013e3281a7ecbb","article-title":"Current concepts and techniques in pterygium treatment","volume":"18","author":"Ang","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ophtha.2012.06.066","article-title":"Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology","volume":"120","author":"Kaufman","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2015.08.023_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","article-title":"Pterygia; pathogenesis and the role of subconjunctival bevacizumab in treatment","volume":"24","author":"Mauro","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.08.023_bib5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0161-6420(97)30197-3","article-title":"Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision","volume":"104","author":"Prabhasawat","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2015.08.023_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0065-1281(96)80038-9","article-title":"Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium","volume":"98","author":"Kria","year":"1996","journal-title":"Acta Histochem"},{"key":"10.1016\/j.clinthera.2015.08.023_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvs136","article-title":"Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases","volume":"153","author":"Shibuya","year":"2013","journal-title":"J Biochem"},{"key":"10.1016\/j.clinthera.2015.08.023_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3892\/ijmm_00000149","article-title":"Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review)","volume":"23","author":"Detorakis","year":"2009","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.clinthera.2015.08.023_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/ACI.0b013e328357b4a2","article-title":"Corneal angiogenesis and lymphagiogenesis","volume":"12","author":"Regenfuss","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2012-301944","article-title":"Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate","volume":"98","author":"Gumus","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/ICO.0b013e3181e16d67","article-title":"Efficacy of intralesional bevacizumab injection in decreasing pterygium size","volume":"30","author":"Fallah Tafit","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2015.08.023_bib13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/ICO.0b013e31821c9b44","article-title":"A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results","volume":"30","author":"Enkvetchakul","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2015.08.023_bib14","first-page":"179","article-title":"Subconjunctival bevacizumab injection in treatment of pterygium","volume":"49","author":"Besharati","year":"2011","journal-title":"Acta Med Iran"},{"key":"10.1016\/j.clinthera.2015.08.023_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2015.08.023_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.clinthera.2015.08.023_bib17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e31820ca63f","article-title":"Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial","volume":"30","author":"Shenasi","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2015.08.023_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archopht.1997.01100160405001","article-title":"Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision","volume":"115","author":"Tan","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00418-012-1019-z","article-title":"Expression of vascular endothelial growth factor C in human pterygium","volume":"139","author":"Fukuhara","year":"2013","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.clinthera.2015.08.023_bib20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/eye.2012.194","article-title":"Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium","volume":"26","author":"Ling","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2015.08.023_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.20092277","article-title":"Thrombospondin 1 inhibits inflammatory lymphagiogenesis by CD36 ligation on monocytes","volume":"208","author":"Cursiefen","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.clinthera.2015.08.023_bib22","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.2353\/ajpath.2010.090829","article-title":"Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphagiogenic activity and suppresses lymph node matastasis","volume":"176","author":"Heishi","year":"2010","journal-title":"Am J Pathol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T03:54:55Z","timestamp":1537329295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815010966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0149291815010966"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.08.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}